MedTrace Logo

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.

NCT04345315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-04-15

No results posted yet for this study

Summary

Translational, prospective / retrospective, non-profit, non-pharmacological study, with cohort characteristics.

The study consists of two parts: the first to study epidemiological aspects of the spread of the disease and the second one to identify infection-related genetic factors.

Conditions

Interventions

OTHER

serological test

serological test assessing IgM and IgG directed against SARS-CoV-2

OTHER

Rapid molecular test

Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab

GENETIC

Next generation Sequencing (NGS) analysis

analysis of genetic variability of virus and host

OTHER

serum chemistry analysis

Analysis of serum chemistry factors and coagulation panel in blood samples

Sponsors & Collaborators

  • AUSL Romagna

    collaborator UNKNOWN

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Giovanni Martinelli, Prof. · IRST IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-27
Primary Completion
2021-03-31
Completion
2022-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04345315 on ClinicalTrials.gov